Sunday, May 27, 2018 10:09:04 AM
I share the same opinion and I think Ping is just pointing out this as well and is basing it on patterns from the past, just so shareholders don't get all giddy and blind to the recent run-up. In fact this is looking a little like the run up in 2015 after uplisting, the only difference is that there are more fundamentals and studies in place to support the valuation now.
Others cry foul just because someone points out the possibility of a raise. For crying out loud, even Microsoft raises money when they don't have to. This was from an article in Thinkgrowth.org. At the time Microsoft raised money it already had approximately $95 billion in cash and equivalents:
"In August of 2016, after just a year, newly appointed Microsoft CEO Satya Nadella had already made tremendous progress in helping Microsoft turn the corner. From the outside, it appeared the company had ample cash on hand to fund both current operations but also invest heavily to drive future growth. However, Microsoft decided to make a bold financial move and sell nearly $20 billion in Microsoft bonds. This happened to be the largest deal in their history and the fifth largest bond deal ever for the market. It was enough to make every financial publication sit up and take notice.
What followed was one of the most productive periods in the company’s history. Heavy investments paved the way for Azure, Microsoft’s cloud computing platform; HoloLens, one of the early-entrants in augmented reality technology; and an acquisition brought in Linkedin. Microsoft didn’t have to raise funds back in 2016. It was not life or death. It was not make or break. But they are a much different company today in part due to that decision."
For years it lagged behind the market and was stuck in a low trading range. Take a look at what Microsoft's stock did since then.
Recent CTSO News
- CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification • GlobeNewswire Inc. • 11/04/2024 12:00:00 PM
- FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review • GlobeNewswire Inc. • 10/22/2024 11:00:00 AM
- CytoSorbents to Report Third Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 10/17/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/09/2024 01:00:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/09/2024 01:00:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 09:25:15 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/01/2024 09:22:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 12:06:10 PM
- CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update • GlobeNewswire Inc. • 10/01/2024 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/01/2024 04:15:18 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/26/2024 09:05:05 PM
- CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference • GlobeNewswire Inc. • 08/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:51:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:58:42 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:57:45 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/16/2024 09:28:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:12:04 PM
- CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/16/2024 08:05:00 PM
- CytoSorbents Reports Second Quarter 2024 Financial and Operational Results • GlobeNewswire Inc. • 08/13/2024 08:19:55 PM
- CytoSorbents Appoints Peter J. Mariani Chief Financial Officer • GlobeNewswire Inc. • 08/13/2024 08:18:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:04:32 PM
- CytoSorbents to Report Second Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:12:56 PM
- CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
FEATURED SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • Nov 7, 2024 8:48 AM
FEATURED SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • Nov 7, 2024 7:00 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM